Profile data is unavailable for this security.
About the company
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
- Revenue in USD (TTM)15.36bn
- Net income in USD-56.10m
- Incorporated2019
- Employees38.00k
- LocationViatris Inc1000 Mylan BoulevardCANONSBURG 15317United StatesUSA
- Phone+1 (724) 514-1800
- Fax+1 (302) 655-5049
- Websitehttps://www.viatris.com/en
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Repligen Corp | 607.45m | 14.84m | 8.87bn | 1.78k | 629.03 | 4.50 | 105.04 | 14.61 | 0.2524 | 0.2524 | 10.74 | 35.29 | 0.2255 | 1.43 | 4.87 | 340,689.80 | 0.551 | 4.38 | 0.6179 | 5.03 | 47.73 | 55.43 | 2.44 | 15.91 | 5.24 | -- | 0.2284 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| Catalent Inc | 4.14bn | -1.18bn | 9.89bn | 17.80k | -- | 2.72 | -- | 2.39 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | -0.4346 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Exact Sciences Corp | 2.53bn | -240.23m | 9.98bn | 6.50k | -- | 3.17 | -- | 3.94 | -1.32 | -1.32 | 13.93 | 17.04 | 0.3998 | 5.28 | 11.96 | 389,975.40 | -3.79 | -9.71 | -4.13 | -10.60 | 73.67 | 74.10 | -9.48 | -28.21 | 1.45 | -- | 0.4323 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.11bn | 438.82m | 11.21bn | 20.00k | 25.53 | 3.08 | 14.49 | 2.73 | 8.52 | 8.52 | 79.74 | 70.67 | 0.5187 | 8.38 | 5.22 | 205,579.80 | 5.69 | 6.46 | 6.53 | 7.62 | 36.45 | 36.99 | 10.97 | 11.58 | 1.37 | 4.80 | 0.4183 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Sarepta Therapeutics Inc | 1.40bn | 16.90m | 12.02bn | 1.31k | 1,595.71 | 12.50 | 204.60 | 8.56 | 0.0797 | 0.0797 | 14.75 | 10.17 | 0.4466 | 0.5758 | 4.66 | 1,067,960.00 | 0.5378 | -21.63 | 0.6577 | -25.75 | 88.18 | 86.65 | 1.20 | -77.05 | 3.44 | -- | 0.5632 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Medpace Holdings Inc | 1.96bn | 312.32m | 12.10bn | 5.80k | 39.80 | 17.98 | 35.61 | 6.17 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| United Therapeutics Corporation | 2.50bn | 1.05bn | 12.26bn | 1.17k | 13.08 | 2.29 | 11.09 | 4.91 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Viatris Inc | 15.36bn | -56.10m | 12.54bn | 38.00k | -- | 0.6263 | 4.74 | 0.8162 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| BIO-TECHNE Corp | 1.15bn | 202.97m | 12.67bn | 3.05k | 63.94 | 6.29 | 40.41 | 10.98 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Incyte Corp | 3.77bn | 745.44m | 12.90bn | 2.52k | 17.44 | 2.39 | 15.53 | 3.42 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Natera Inc | 1.21bn | -365.46m | 13.20bn | 3.28k | -- | 16.55 | -- | 10.92 | -3.13 | -3.13 | 10.31 | 6.50 | 0.8673 | 14.36 | 4.51 | 368,237.70 | -26.23 | -36.17 | -33.37 | -46.60 | 50.28 | 45.88 | -30.24 | -56.15 | 3.98 | -- | 0.3141 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 14.14bn | 1.45k | 38.61 | 5.92 | 36.05 | 7.13 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 14.41bn | 3.40k | 71.84 | 2.84 | 46.37 | 5.83 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Data as of May 24 2024. Currency figures normalised to Viatris Inc's reporting currency: US Dollar USD
41.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 135.93m | 11.45% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 62.76m | 5.29% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 62.22m | 5.24% |
| Davis Selected Advisers LPas of 31 Mar 2024 | 57.47m | 4.84% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 56.20m | 4.73% |
| Geode Capital Management LLCas of 31 Mar 2024 | 28.52m | 2.40% |
| Invesco Capital Management LLCas of 31 Mar 2024 | 27.82m | 2.34% |
| Pacer Advisors, Inc.as of 31 Mar 2024 | 26.42m | 2.22% |
| Columbia Management Investment Advisers LLCas of 31 Mar 2024 | 20.33m | 1.71% |
| Rubric Capital Management LPas of 31 Mar 2024 | 18.44m | 1.55% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
